Gerrit Hauck - Basilea Pharmaceutica Chief Officer

All Insiders . USA . 
Stock . Basilea Pharmaceutica AG . Stakeholders . Insider . Gerrit Hauck
BPMUF Stock  USD 52.83  0.00  0.00%   

Executive

Dr. Gerrit Hauck is Chief Technology Officer of the Company. Dr. Hauck joins Basilea from Sanofi, where he was Cluster Head Synthetic Molecules. In this role he was overseeing most of the company technical development programs for synthetic molecules from preclinical candidates to launch. At the same time he was a member of Sanofi Research Stage Gate Committee, which is responsible for the transition of candidate molecules from research into development. He also brings significant experience in implementing strategic projects with contract manufacturing organizations since 2018.
Age 59
Tenure 6 years
Professional MarksPh.D
Phone41 61 606 11 11
Webhttps://www.basilea.com
Hauck graduated as a pharmacist from the University of Heidelberg, Germany and holds a PhD from Saarland University, Germany.

Basilea Pharmaceutica Management Efficiency

The company has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Basilea Pharmaceutica's management efficiency ratios could be used to measure how well Basilea Pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.
Basilea Pharmaceutica AG has accumulated 94.54 M in total debt. Basilea Pharmaceutica has a current ratio of 1.33, which is within standard range for the sector. Debt can assist Basilea Pharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Basilea Pharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Basilea Pharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Basilea to invest in growth at high rates of return. When we think about Basilea Pharmaceutica's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Daniel AndersonCrispr Therapeutics AG
N/A
Joshua DunnGinkgo Bioworks Holdings
N/A
Oliver HennigBioNTech SE
N/A
Marcia SellosMouraEyepoint Pharmaceuticals
N/A
Susan KimCrispr Therapeutics AG
N/A
Lisa BirringerBioNTech SE
N/A
JD EsqApellis Pharmaceuticals
51
Christina RossiBlueprint Medicines Corp
47
Steven CPAGinkgo Bioworks Holdings
N/A
Indrani JDAlnylam Pharmaceuticals
51
Robert FrancomanoSellas Life Sciences
57
Sylke MaasBioNTech SE
N/A
Brad MillerModerna
51
Allison MDModerna
N/A
Myriam MDCureVac NV
58
Daryn LewisWave Life Sciences
N/A
Evan LippmanAlnylam Pharmaceuticals
N/A
Saraswathy NochurAlnylam Pharmaceuticals
63
Erika TrahanNovavax
N/A
Caroline MDApellis Pharmaceuticals
57
Andrew ElnatanSellas Life Sciences
N/A
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA PHARMACEUTICA is traded on OTC Exchange in the United States. Basilea Pharmaceutica AG [BPMUF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Asset0.0261

Basilea Pharmaceutica Leadership Team

Elected by the shareholders, the Basilea Pharmaceutica's board of directors comprises two types of representatives: Basilea Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Basilea. The board's role is to monitor Basilea Pharmaceutica's management team and ensure that shareholders' interests are well served. Basilea Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Basilea Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lutz Wevelsiep, Head Affairs
Adesh Kaul, Chief Officer
Damian Heller, Gen Sec
Gerrit Hauck, Chief Officer
David Veitch, Chief Commercial Officer, Member of the Management Committee
Ursula Eberhardt, Head HR
Marc MD, Chief Officer
Peer Schroder, Head Relations
Dietrich Stber, Head Services
Laurenz Kellenberger, Chief Scientific Officer

Basilea Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Basilea Pharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset0.0261
Profit Margin0.01 %
Operating Margin0.06 %
Current Valuation724.26 M
Shares Outstanding11.93 M
Shares Owned By Insiders3.07 %
Shares Owned By Institutions29.13 %
Price To Earning200.00 X
Price To Sales4.09 X
Revenue148.12 M

Currently Active Assets on Macroaxis

VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C
MSFTMicrosoft
GMGeneral Motors

Other Information on Investing in Basilea Pink Sheet

Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY